NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Guideline Centre (UK). Emergency and acute medical care in over 16s: service delivery and organisation. London: National Institute for Health and Care Excellence (NICE); 2018 Mar. (NICE Guideline, No. 94.)
Emergency and acute medical care in over 16s: service delivery and organisation.
Show detailsTable 2Summary of studies included in the review (regular in-hospital pharmacy support)
Study | Intervention and comparison | Population | Outcomes | Comments |
---|---|---|---|---|
Claus 201413 RCT | Pharmacist present on the ward. Duties included making active recommendations and performing patient follow-up. |
Surgical ICU admissions (n=69) within a university hospital in Belgium. Inclusion - over 16 years of age, length of stay greater than 48 hours. Exclusion - none stated. | In-hospital mortality. |
No pharmacist screening or discharge services. Patients crossed to intervention group if the pharmacist was asked by the caregiver to give advice. Pharmacist saw all patients, but recommendations were not passed onto the caregiver in the control group. Intervention conducted by 1 of 2 clinical pharmacists. |
Iowa Continuity of Care Study trial: Farris 201418 (Farley 201417) RCT |
Pharmacy case manager. Duties included medication reconciliation, ward visits and discharge service. Versus Nurse based medication reconciliation and discharge service. |
General medicine, family medicine, cardiology or orthopaedic admissions (n=631) within an academic tertiary care hospital in the USA. Inclusion - patients with certain disease classifications: hypertension, hyperlipidaemia, heart failure, coronary artery disease, myocardial infarction, stroke, transient ischemic attack, asthma, chronic obstructive pulmonary disease or receiving oral anticoagulation. |
Preventable adverse drug events in-hospital; post-discharge (90 days) hospital Readmission at 30 days; Admission at 90 days Medication appropriatene ss index (MAI) at discharge; 30 days; 90 days. |
Farley 2010 indicates that the initial medication reconciliation is normally undertaken by a nurse in the control group. Unclear number of pharmacists involved. Data was extracted from Farris 2014 MAI is based on 6 criteria. |
Gillespie 200921 RCT |
Pharmacist present on the ward. Duties included taking part in the rounding team, documenting medication history, and discharge counselling. Versus No pharmacist involvement in the healthcare team at the ward level. |
Patients (n=400) admitted to the 2 acute internal study wards at a University teaching hospital in Sweden. Inclusion - 80 years of age. Exclusion - previously been admitted to the study wards during the study period or had scheduled admissions. |
Overall survival at 12 months, reported as hazard ratio. Admission at 12 months |
A follow-up telephone call to patients 2 months after discharge was conducted in the intervention group Admission and discharge documentation filled by physicians and nurses in comparison group Intervention conducted by 1 of 3 clinical pharmacists. During follow-up period intervention patients received enhanced care again, but were excluded if admitted during the intervention period. |
Kucukarslan 200335 Quasi-RCT |
Pharmacist present on the ward. Duties included taking part in the rounding team, documenting medication history, and discharge counselling. Versus Standard care from 1 pharmacist (implication in paper that this is not ward-based). |
All patients (n=165) admitted to 1 of the 2 internal medicine study wards within a tertiary care hospital in the USA. Inclusion - admitted to the internal medicine service and remained in the same patient care unit until discharge. Exclusion – none given. |
Avoidable adverse drug events until discharge. Length of stay in-hospital (reported as mean difference). Re-admission (unclear follow-up time, reported as percentage reduction). |
Admitting process was based on the availability of beds and physician service. Pharmacist on the ward Mon-Fri. Intervention conducted by 1 of 2 clinical pharmacists. Usual care involved identification of medication problems retrospectively through records |
Shen 201158 China RCT |
Clinical pharmacist part of the treating team – communicated any potentially inappropriate antibiotic use (indication, choice, dosage, dosing schedule, duration, conversion) with the physician to discuss and make recommendations. Versus. Standard treatment strategies performed by the physicians and nurses without pharmacist involvement. |
n=354 inpatients in 2 respiratory wards diagnosed with respiratory tract infections. Exclusion criteria: transferred from other medical departments; transferred to other medical departments for further treatment; already received antibiotics before admission; did not receive antibiotics during hospitalisation. | Length of stay. | Regular-in ward pharmacist support strata. |
Scullin 200757 RCT |
Pharmacist present on the ward. Duties included admission services, in-patient monitoring, and discharge services Versus Traditional clinical pharmacy services (no further details given). |
Admitted patients (n=762) to the 4 medical study wards within 3 general hospitals in northern Ireland. One of the following criteria: taking at least 4 regular medication, were taking a high risk drug(s), were taking antidepressants and were 65 years old or older, had a hospital admission within the last 6 months, prescribed antibiotics on day 1 of admission. Exclusion - scheduled admissions and patients admitted from private nursing homes. |
Admission at 12 months. Mortality at 12 months. Length of stay. | Intervention conducted by 1 of 4 clinical pharmacists/pharm acy technician pairs. |
Spinewine 200759 RCT |
Pharmacist present on the ward. Duties included taking part in the rounding team, documenting medication history, and discharge counselling. Versus Usual care (no details of any clinical pharmacist involvement). |
All eligible patients (n=186) admitted to the Geriatric Evaluation and Management (GEM) unit within a university teaching hospital in Belgium. GEM unit accepted patients over 70 years of age. |
Rate of death at 1 year follow-up. Satisfaction with information received. Admission at 12 months. Medical appropriateness index. |
Pharmacist was on the unit for 4 days a week. Intervention conducted by a single clinical pharmacist. GEM team consisted of 2 geriatricians, 2 residents, nurses, 2 physiotherapists, a social worker, a psychologist, and an occupational therapist. MAI is based on 10 criteria (not defined). |
RCT |
Interventions by clinical pharmacists including individual drug regimens, attending daily medical rounds, advice to physicians, education of medical staff, patient education on lifestyle changes, psychological interventions such as stress reduction, medication counselling at discharge, monthly follow up telephone calls post-discharge. Versus Conventional medical treatment without pharmacist participation. |
n=90 patients admitted to the cardiology ward in a hospital in China. Inclusion criteria: diagnosis of CHD by physician, accepted ≥4 kinds of drugs, ≥18 years, primary high school education, able to complete the study, available for telephone follow up. Exclusion criteria: pregnant/lactating women, patients enrolled in other studies, severe co-morbidities, family history of psychosis, and barriers to communication. |
Avoidable adverse events (adverse drug reactions). Patient and/or carer satisfaction. |
- Table 2, Summary of studies included in the review (regular in-hospital pharmacy...Table 2, Summary of studies included in the review (regular in-hospital pharmacy support) - Emergency and acute medical care in over 16s: service delivery and organisation
- Mus musculus serine protease 37 (Prss37), transcript variant 1, mRNAMus musculus serine protease 37 (Prss37), transcript variant 1, mRNAgi|2451976087|ref|NM_026317.3|Nucleotide
- Mus musculus partial mRNA for hypothetical protein (ORF1)Mus musculus partial mRNA for hypothetical protein (ORF1)gi|13398294|emb|AJ404329.1|Nucleotide
- Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4), mRN...Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4), mRNAgi|19923257|ref|NM_004567.2|Nucleotide
- L1TD1 LINE1 type transposase domain containing 1 [Homo sapiens]L1TD1 LINE1 type transposase domain containing 1 [Homo sapiens]Gene ID:54596Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...